SecBot SecBot

ENTA drug pipeline

$10.67
−2.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bearish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhaseApproved (Pfizer)
Time to marketPaxlovid is already approved and marketed by Pfizer. Enanta has no timeline to market for any of its own pipeline drugs; zelicapavir's registrational Phase 2b/3 data is expected in 2027, with potential FDA submission following positive results.

Paxlovid nirmatrelvir and ritonavir Updated Oct 30

What to watch

Paxlovid is Pfizer's drug, not Enanta's. Enanta's patent litigation against Pfizer over Paxlovid has now been fully resolved against Enanta on both sides of the Atlantic: the US Federal Circuit invalidated the '953 patent in June 2026 (en banc denied September 2026), and the UPC invalidated the European EP 265 patent on October 29, 2026. With no further appeal options disclosed, the litigation catalyst is dead. Enanta's stock now trades entirely on its RSV pipeline (zelicapavir Phase 2b/3 RESOLVE trial, topline 2027; EDP-323 Phase 2a) and its AbbVie royalty revenue stream. The next hard catalyst is Q4 2026 earnings on November 16, 2026.

Bull case
  • Enanta has $211.5M in cash (June 30, 2026) with runway into 2029, providing financial stability to advance its RSV pipeline without near-term dilution.
  • Zelicapavir (RSV N-protein inhibitor) showed positive Phase 2b data in high-risk adults (Sept 2025) and has Fast Track designation from the FDA; the registrational RESOLVE trial began dosing October 26, 2026.
  • EDP-323 (RSV L-protein inhibitor) demonstrated 'unprecedented antiviral activity' in a Phase 2a human challenge study, with statistically significant viral load and symptom reductions.
Bear case
  • Enanta's US and European Paxlovid-related patents have both been ruled invalid (Federal Circuit June 2026, UPC October 2026), eliminating any potential royalty or damages stream from Pfizer's Paxlovid sales.
  • Enanta has no approved products of its own; its only revenue ($14.36M in Q3 2026) comes from AbbVie HCV royalty payments that are declining.
  • The RSV pipeline is still early-stage: zelicapavir's registrational Phase 2b/3 trial (RESOLVE) only began dosing in late October 2026, with topline data not expected until 2027, leaving a long binary-free period.
● neutral
Impact
PhaseApproved (generic, off-patent)
Time to marketAlready on market since 1996 (Norvir); generic widely available.

ritonavir Updated Oct 30

What to watch

Ritonavir itself is not an Enanta catalyst. The two patent-litigation "lottery tickets" tied to ritonavir-containing products have now both come up empty: the US patent was invalidated in June 2026 and the EU patent was revoked on October 29, 2026. Enanta's next meaningful binary catalyst is the Phase 2b data readout from the RESOLVE trial of zelicapavir for RSV, expected in 2027. The company also reports fiscal Q4 2026 earnings on November 16, 2026, which will show the continuing trajectory of its declining HCV royalty revenue.

Bull case
  • Enanta's historical partnership with AbbVie demonstrated its drug discovery capabilities: Enanta-discovered HCV protease inhibitors were part of multi-billion-dollar franchise products (Viekira, MAVYRET).
  • The now-resolved Paxlovid patent litigation, while unsuccessful, highlighted that Enanta's research into coronavirus protease inhibitors was early and scientifically legitimate, validating its chemistry platform.
  • With the litigation overhang removed, investor attention can now focus entirely on Enanta's RSV pipeline (zelicapavir, EDP-323), which represents the company's actual value proposition.
Bear case
  • Enanta's two patent-infringement cases against Pfizer over Paxlovid (which contains ritonavir) both failed: the US Federal Circuit invalidated the patent in June 2026 and the UPC revoked the European counterpart on October 29, 2026, eliminating any potential royalty stream from Paxlovid sales.
  • Enanta's revenue is entirely dependent on declining HCV royalties from AbbVie's MAVYRET/MAVIRET, which fell 21% year-over-year to $14.4 million in fiscal Q3 2026. This revenue stream does not involve ritonavir and is in structural decline as the HCV cured-patient pool shrinks.
  • The company has no approved products of its own and is a clinical-stage biotech burning cash ($19.5 million net loss in Q3 2026), with its pipeline focused on unproven RSV treatments facing a competitive landscape that includes approved vaccines and therapies from larger players.

Other drugs in filings and trials

no drug report yet

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
EDP-938A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.Phase 2Completed · results187Jun 23, 2025